Nanoform and Celanese Explore Ways to Enhance Drug Delivery
Together, Nanoform and Celanese will investigate the potential for enabling next-generation drug delivery devices by combining Nanoform’s nanoparticle platform technologies and Celanese’s VitalDose® EVA copolymer delivery technology.
Nanoform’s final clinical results confirm value proposition to the pharma industry
Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced the completion and final results of its clinical study.
Nanoform and Aprecia collaborate to advance 3D printed Nanomedicines
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Aprecia, the 3DP (three-dimensional printing) pharmaceutical company, announce that they are exploring the synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms.
Nanoform launches next-generation STARMAP® v2.0, the AI-based drug candidate selection tool for CESS®
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, has today launched the next generation of its STARMAP® AI (artificial intelligence) platform, v2.0.
Additional Positive Interim Results from Nanoform’s Clinical Study
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.